UK cell therapy start-up agrees AstraZeneca partnership worth up to $2bn

Biopharmaceutical UCL spinout Quell Therapeutics has signed a major research collaboration and licensing deal with AstraZeneca to develop treatments for two autoimmune diseases.

Read: Financial Times